ArticleJournal of clinical immunology2006
Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo.
Article in Journal of clinical immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05726383 (MISTOSUS), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Resectable Osteosarcoma
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Mistletoe therapy in oncology.The Cochrane database of systematic reviews · 2008Pooled it
- MISTOSUS: a phase II trial ofFuture oncology (London, England) · 2026Trial
- Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2009Trial
- Phytonutrient Profiles of Mistletoe and Their Values and Potential Applications in Ethnopharmacology and Nutraceuticals: A Review.Molecules (Basel, Switzerland) · 2025Review
- Immune Response Activation and Hepatoprotective Activity ofInternational journal of food science · 2025Article
- Novel drug isolated from mistletoe (1RSC advances · 2020Article
- Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.Integrative cancer therapies · 2018Article
- Phenolic compounds fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018Article
- Observational
- Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.BMC complementary and alternative medicine · 2017Observational
- Jacalin-Activated Macrophages Exhibit an Antitumor Phenotype.BioMed research international · 2016Article
- Article
- The supplementation of Korean mistletoe water extracts reduces hot flushes, dyslipidemia, hepatic steatosis, and muscle loss in ovariectomized rats.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.BMC complementary and alternative medicine · 2014Article
- Preclinical and clinical effects of mistletoe against breast cancer.BioMed research international · 2014Review
- Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa.Nature reviews. Microbiology · 2011Review
- Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2.PloS one · 2011Article
- Article
- Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.Journal of clinical immunology · 2007Article
- A randomized placebo-controlled double-blinded study comparing oral and subcutaneous administration of mistletoe extract for the treatment of equine sarcoid disease.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even though mistletoe extracts have been in clinical use for centuries their exact mode of action is still unknown. Currently, the application scheme for registered preparations is a dose-escalating scheme to thus reduce side effects. In this study, healthy controls and patients were evaluated for their immunologic response to treatment with a standardized mistletoe extract (Iscador). It shows a strong effect as adjuvant that induces TNF-alpha and IL-12, which was partly mediated via CD14. Desensitization of the TNF-alpha response could be shown after repeated application in vitro and in vivo. Furthermore, Iscador induces a specific lymphocyte sensitization upon multiple injections and production of IgG1- and IgG3 -mistletoe antibodies. Remarkably, a systemic bystander effect (heterologous immunity against other recall antigens) was observed after long-term treatment. In conclusion, dose-escalation reduces the monocyte-related clinical side effects. A T-lymphocyte sensitization stimulates mainly a specific Th1 response. The most interesting clinical long-term effect is the bystander stimulation of various memory T cells that might mediate in vivo antitumor and antiinfectious T-cell response under mistletoe-extract immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.